Provided by Tiger Trade Technology Pte. Ltd.

Roivant Sciences Ltd.

40.94
-0.8700-2.08%
Post-market: 40.25-0.6900-1.69%19:42 EDT
Volume:6.54M
Turnover:266.60M
Market Cap:29.58B
PE:-87.11
High:41.41
Open:41.27
Low:40.22
Close:41.81
52wk High:42.50
52wk Low:13.81
Shares:722.41M
Float Shares:581.00M
Volume Ratio:0.60
T/O Rate:1.13%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4700
EPS(LYR):-0.5400
ROE:-8.52%
ROA:-16.48%
PB:6.99
PE(LYR):-75.81

Loading ...

Stock Track | Roivant Sciences Soars 9.89% in Pre-Market on Unexpected Q4 Profit from Moderna Lawsuit Settlement

Stock Track
·
May 20

Immunovant Inc Q4 net loss misses on higher R&D costs

Reuters
·
May 20

Roivant posts unexpected Q4 profit due to Moderna lawsuit settlement gain

Reuters
·
May 20

Earnings Flash (ROIV) Roivant Posts Fiscal Q4 EPS From Continuing Operations $0.28

MT Newswires Live
·
May 20

Roivant Q4 swings to profit of $355.7 million; revenue falls to $2.52 million

Reuters
·
May 20

Roivant Sciences Q4 Sales $2.520M Miss $3.820M Estimate

Benzinga Earnings
·
May 20

BRIEF-Roivant Sciences Q4 Revenue USD 2.52 Million

Reuters
·
May 20

Immunovant Q4 net loss widens to $147.86 million

Reuters
·
May 20

Roivant Sciences Q4 Operating Expenses USD 357.515 Million

THOMSON REUTERS
·
May 20

Roivant Sciences Q4 EPS USD 0.28

THOMSON REUTERS
·
May 20

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update

THOMSON REUTERS
·
May 20

A Look At Roivant Sciences (ROIV) Valuation As IMVT-1402 And Earnings Outlook Draw Investor Focus

Simply Wall St.
·
May 19

Roivant Sciences price target raised to $29.50 from $29 at BofA

TIPRANKS
·
May 14

Earning Preview: Roivant Sciences Ltd. revenue is expected to decrease by 92.94%, institutional views are bullish

Earnings Agent
·
May 13

Immunovant to report fourth-quarter, fiscal-year results, give business update on conference call

Reuters
·
May 12

Roivant schedules quarterly, fiscal-year results call and webcast

Reuters
·
May 12

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026

THOMSON REUTERS
·
May 12

Immunovant director Robert Graham Susman sells 2,502 shares for $67,988.34

Reuters
·
May 02

Zura Bio names Marlyn Mathew principal financial, accounting officer after CFO exit

Reuters
·
Apr 24

Roivant CEO Matthew Gline disposes of 289,774 common shares for $8.45 million

Reuters
·
Apr 21